TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast

Breast Cancer Research and Treatment

Volumn 41, Issue 2, 1996, Pages 103-109

  Chitemerere, Margaret ^a   Andersen, Tone Ikdahl ^a   Holm, Ruth ^a   Karlsen, Frank ^a   Børresen, Anne Lise ^a   Nesland, Jahn Marthin ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Atypical ductal hyperplasia; DCIS; p53; Tumor development; Tumor suppressor genes

Indexed keywords

PROTEIN P53;

ARTICLE; BREAST CARCINOMA; BREAST HYPERPLASIA; CONTROLLED STUDY; FEMALE; GEL ELECTROPHORESIS; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CELL DIFFERENTIATION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENES, P53; HUMANS; HYPERPLASIA; MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029831178     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01807155     Document Type: Article

References (37)

1. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1993
2. Donehower LA, Bradley A: The tumor suppressor p53. Biochim Biophys Acta 1155: 181-205, 1993
3. Harris CC, Hollstein M: Clinical implications of the p53 tumour suppressor gene. N Engl J Med 329: 1318-1327, 1993
4. Hollstein M, Risce K, Greenblatt MS, Soussi T, Fuchs R, Sørli T, Hovig E, Smith-Sørensen B, Montesano R, Harris CC: Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acid Res 22: 3551-3555, 1994
5. Finlay CA, Himnds PW, Tan TH: Activating mutations for transformation by p53 produce a gene product that forms an fsc 70-p53 complex with an altered half-life. Mol Cell Biol 8: 531-539, 1988
6. Gronstajaski RM, Goldberg AL, Pardee AB: Energy requirement for degradation of tumour-associated protein p53. Mol Cell Biol 4: 442-448, 1984
7. Lane D: The regulation of p53 function: Steiner award lecture. Int J Cancer 57: 623-627, 1994
8. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992
9. Bàrtek J, Bàrtkovà J, Vojtesek B, Staskovà Z, Rejthar A, Kovarik J, Lane DP: Patterns of expression of the p53 tumor suppressor in human breast tissues and tumors in situ and in vitro. Int J Cancer 46: 839-844, 1990
10. Davidoff AM, Kerns BM, Pence JC, Marks JR, Iglehart DJ: p53 alterations in all stages of breast cancer. J Surg Onc 48: 260-267, 1991
11. Walker RA, Dearing SJ, Lane DP, Varley JM: Expression of p53 protein in infiltrating and in situ breast carcinomas. J Pathol 165: 203-211, 1991
12. Thor AD, Moore DM, Edgerton SM, Kawasaki ES, Reishaus E, Lynch HT, Marcus JN, Schwartz L, Chen L, Mayall BH, Smith HS: Accumulation of p53 tumour suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84: 845-855, 1992
13. Poller DN, Hutchins CE, Galea M: p53 protein expression in breast carcinoma: Relationship to expression of epidermal growth factor receptor, c-erb 2 protein overexpression, and oestrogen receptor. Br J Cancer 66: 583-588, 1992
14. Poller DN, Roberts EC, Bell JA, Elston CW, Blamey RW, Ellis IO: p53 protein expression in mammary ductal carcinoma in situ. Relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. J Pathol 24: 463-168, 1993
15. Tsuda H, Iwya K, Fukutomi T, Hirohashi S: p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinoma of high histologic grade. Jpn J Cancer Res 84: 394-401, 1993
16. Bhargava V, Thor A, Deng G, Ljung B-M, Moore L, Waldman F, Benz C, Goodson W, Mayall B, Chew K, Smith HS: The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer. Mod Pathol 7: 361-368, 1994
17. O'Malley FP, Unencak Jones CL, Dupont WD, Parl F, Mannings S, Page DL: p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. Lab Invest 71: 67-72, 1994
18. Zafrani B, Leroyer A, Fourquel A, Laurent M, Trophilme D, Validire P, Sastre Garau X: Mammographically detected duetal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 protein, and proliferation activity. Semin Diagn Pathol 11: 208-214, 1994
19. Coles C, Condie A, Chetty U, Steel M, Evans HJ, Prosser J: p53 mutations in breast cancer. Cancer Res 52: 5291-5298, 1992
20. Thompson AM, Anderson TJ, Condie A, Prosser J, Chetty U, Carter DC, Evans HJ, Steel CM: p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer 50: 528-532, 1992
21. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Børresen A-L: Prognostic significance of TP53 in breast carcinoma. Br J Cancer 68: 560-548, 1993
22. Lipponen P, Aaltomaa HJ, Syrjänen S: p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 55: 51-56, 1993
23. Thorlacius S, Børresen A-L, Eyfjord JE: Somatic p53 mutations in human breast carcinomas in an Icelandic population: A prognostic factor. Cancer Res 53: 1637-1641, 1993
24. Azzopardi JG: Problems in breast pathology. In: Bennington JL (ed.) Major Problems in Pathology. W.B. Saunders Company Ltd, London, Philadelphia, Toronto, 1979, Vol 11
25. Holland R, Peterse L, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, Zafrani B: Ductal carcinoma in situ: A proposal for a new classification. Seminars in Diagnostic Pathology. Ductal Carcinoma In situ. W. B. Saunders Company Ltd, Philadelphia, 1994, Vol 11, pp 167-180
26. Mies C, Hauldsworth J, Chaganti RSK: Extraction of DNA from paraffin blocks for Southern blot analysis. Am J Surg Pathol 15(2): 169-174, 1991
27. Kunkel LM, Smith KD, Boyer SH, Borgaonkar DS, Wachtel SS, Miller OJ, Breg WR, Jones HW Jr, Rary JM: Analysis of human Y-chromosome-specific reiterated DNA in chromosome variants. Proc Natl Acad Sci USA 74: 1245-1249, 1977
28. Børresen A-L, Hovig E, Smith-Sørensen B, Malkin D, Lystad S, Andersen TI, Nesland JM, Isselbacher KJ, Friend SH: Constant Denaturant Gel Electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci USA 88: 8405-8409, 1991
29. Condie C. Eeles R, Børresen A-L, Coles C, Cooper C, Prosser J: Detection of point mutations in the p53 gene: comparison of single-strand conformation polymorphism, constant denaturant gel electrophoresis, and hydroxylamine and osmium tetroxide techniques. Human Mutation 2: 58-66, 1993
30. Andersen TI, Børresen A-L: Alterations of the TP53 gene as potential molecular marker in breast carcinomas: advantages of using CDGE in mutation detection. Diagn Molec Pathol (In press)
31. Hsu SM, Raine L, Fanger H: A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptides hormones with radioimmunoassay antibodies. Am J Clin Pathol 75: 734-738, 1981
32. Bobrow LG, Happerfield LC, Gregory WM, Springall RD, Millis R: The classification of ductal carcinoma in situ and its association with biological markers. In: Santa Cruz DJ (ed.) Seminars in Diagnostic Pathology. Ductal Carcinoma In situ. W.B. Saunders Company Ltd, Philadelphia, 1994, Vol 11, pp 199-207
33. Holm R, Skomedal H, Helland Å, Kristensen G, Børresen A-L, Nesland JM: Immunochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri. J Pathol 169: 21-26, 1993
34. Holm R, Abeler VM, Skomedal H, Nesland JM: Overexpression of p53 protein and c-erb-2 protein in small cell carcinoma of the cervix uteri. Zentralbl Pathol 139: 153-156, 1993
35. Purdie CA, O'Grady J, Piris J, Wyllie AH, Bird CC: p53 expression in colorectal tumors. Am J Pathol 138: 807-812, 1991
36. Børresen A-L, Andersen TI, Eyfjörd JE, Corneli RS, Thorlacius S, Borg Å, Johansson U, Theillet C, Scherneck S, Hartmann S, Cornelisse CJ, Hovig E, Devilee P: TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in zinc-binding domains. Genes Chrom Cancer 14: 71-75, 1995
37. Hall AP, Mackee PH, Menage HP, Dover R, Lane DP: High levels of p53 protein in UV-irradiated normal skin. Oncogene 8: 203-207, 1993